Welcome to
Sanofi in Canada
Toggle navigation
About Us
Science & Innovation
Products and Resources
Patient Support
Our Responsibility
Careers
Media
Toggle navigation
News Releases
Subscribe
Media Contacts
Social Media
News
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Subscribe
Year
All Years
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Asset Types
Photos
Video
Audio
Documents
Events
Standard
Feb 3, 2026
Rezurock® now reimbursed in Ontario and British Columbia for people living with chronic graft-versus-host disease (GVHD)
Nov 10, 2025
Eight out of 10 infants and newborns in Canada have access to RSV prevention with Beyfortus® this season
Nov 6, 2025
Rezurock® now covered in Quebec for people living with chronic graft-versus-host disease (GVHD)
Nov 3, 2025
Dupixent® approved in Canada as targeted therapy for chronic spontaneous urticaria (CSU)
Oct 22, 2025
Dupixent® (dupilumab injection) approved in Canada for adults with inadequately controlled Chronic Obstructive Pulmonary Disease (COPD)
Oct 21, 2025
Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
Jun 9, 2025
Sanofi Appoints James Guy as Country Lead, Canada and General Manager, Specialty Care
Photos
1
May 14, 2025
Kevzara® approved in Canada for the treatment of adults with polymyalgia rheumatica (PMR)
May 5, 2025
Health Canada has granted approval for Tzield®, the first and only disease-modifying therapy in autoimmune type 1 diabetes in Canada
Apr 22, 2025
Sarclisa® approved in Canada for patients with newly diagnosed multiple myeloma (NDMM)
Mar 27, 2025
Media Update: Once-weekly ALTUVIIIO® approved in Canada for the treatment of adults, adolescents and children living with hemophilia A
Oct 28, 2024
Beyfortus® immunization to protect infants from RSV has begun
Sep 12, 2024
DUPIXENT® (dupilumab injection) approved in Canada for the treatment of children aged 1 year and older with eosinophilic esophagitis (EoE)
Jul 26, 2024
Fluzone® High-Dose Quadrivalent vaccine remains preferentially recommended to protect adults 65 years of age and older against influenza
Jul 25, 2024
Ontario Ministry of Health Announces a Universal Public Program with Beyfortus® this RSV Season
Jun 18, 2024
Sanofi Canada celebrates winners of the 2024 Biogenius Competition and awards fourth annual Biogenius Grants
Photos
1
May 31, 2024
Quebec Ministry of Health Announces Universal Public Program with Beyfortus® this Upcoming RSV Season
May 30, 2024
SANOFI OPENS NEW ADVANCED VACCINES FACILITY, STRENGTHENING ITS COMMITMENT TO BIOMANUFACTURING IN CANADA
Photos
1
May 21, 2024
The National Advisory Committee on Immunization recommends BEYFORTUS® to protect all infants against RSV
Apr 18, 2024
Quebec's INESSS recommends BEYFORTUS® for the prevention of RSV for all infants 8 months of age and younger(1)
Apr 16, 2024
Sanofi Canada invests $180M CAD to build and update infrastructure to minimize environmental footprint at its Toronto Campus by 50%
Photos
1
Mar 19, 2024
2024 Sanofi Biogenius Canada Grants open for applications
Photos
1
Feb 20, 2024
JDRF Canada and Sanofi Canada partner to raise awareness about autoimmune type 1 diabetes and the critical role of screening in its early detection
Photos
1
Jan 30, 2024
Sanofi Canada is celebrating 110 years of innovative health solutions for Canadians
Jul 25, 2023
Sanofi Consumer Healthcare North America Earns B Corp Certification in Recognition of Environmental, Social Impact
Jul 17, 2023
Dupixent® (dupilumab injection) receives marketing authorization for prurigo nodularis
Jul 6, 2023
Sanofi Canada awards third annual Sanofi Biogenius Canada Grants to enhance STEM learning for students
Jun 13, 2023
Sanofi Canada Celebrates Winners of the 2023 Sanofi Biogenius Canada Competition
Jun 12, 2023
Icy Hot® Partners with KidSport Canada to Help Kids Get in the Game
May 4, 2023
DUPIXENT® (dupilumab injection) is now approved in Canada for the treatment of adult and adolescent patients (12+) with Eosinophilic Esophagitis
May 1, 2023
Libtayo® (cemiplimab) in Combination with Chemotherapy now approved in Canada for the First-line Treatment of Advanced Non-small Cell Lung Cancer
May 1, 2023
Sanofi Canada and Diabetes Care Community announce a collaboration to support the emotional well-being journey of Canadians living with diabetes
Apr 24, 2023
Health Canada approves BEYFORTUS™ (nirsevimab) for the prevention of RSV disease in infants
Apr 20, 2023
DUPIXENT® (dupilumab injection) now approved in Canada for children as young as six months old with severe atopic dermatitis
Mar 21, 2023
Notice of Compliance issued regarding Rezurock(TM) (belumosudil tablets)
Mar 8, 2023
Sanofi Canada Maintains Gender Parity Certification, Achieving Platinum Level
Photos
1
Jan 18, 2023
Health Canada accepts nirsevimab regulatory submission for infant RSV
Oct 26, 2022
Canadians Encouraged to Live "In Range" to Better Manage their Diabetes
Jun 22, 2022
Sanofi to Launch Artificial Intelligence Centre of Excellence in Toronto
Jun 16, 2022
Sanofi Canada awards second annual Sanofi Biogenius Canada Grants, supporting access to hands-on STEM learning for Canadian students
Jun 15, 2022
Sanofi Canada announces winners of 2022 Sanofi Biogenius Canada Competition
Jun 14, 2022
Sanofi Canada furthers commitment to Canadians living with diabetes through mental health resources provided by MindBeacon
May 10, 2022
Sanofi Biogenius Canada Competition returns to Canada-Wide Science Fair
May 3, 2022
Sanofi achieves the third year of Gold-level Gender Parity Certification
Mar 28, 2022
Dupixent® (dupilumab injection) now approved in Canada for the treatment of severe asthma in children aged six to 11 years with type 2 inflammation
Mar 25, 2022
Libtayo® (cemiplimab) now approved in Canada for the treatment of recurrent or metastatic cervical cancer
Jan 25, 2022
Sanofi Canada named one of Forbes Canada's Best Employers for 2022
Dec 9, 2021
Sanofi Canada supports Canada's Walk of Fame in its induction of Frederick Banting, Charles Best, James Collip and John Macleod in the 100th anniversary year of their discovery of insulin
Nov 15, 2021
Nexviazyme™ (avalglucosidase alfa for injection) is now approved in Canada for patients with late-onset Pompe disease (acid α-glucosidase deficiency)
Nov 10, 2021
Canadians living with diabetes want increased mental health resources, are interested in taking a 360-approach towards holistic car
Show
5
10
25
50
100
per page
«
1
2
3
»
